This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
Subacute spongiform encephalopathy (SSE) is a collective term for a group of neurodegenerative diseases in which spongiform vacuolation forms within brain tissue. This characteristic pathological finding appeared in sporadic neuropathological reports from the early 20th century, but its significance began to be understood systematically through research in the 1950s–60s on kuru among the Fore people of Papua New Guinea. Kuru is a fatal neurological disease transmitted through the cannibalistic rituals of the Fore people (the custom of consuming the brains of the dead), and D. Carleton Gajdusek first demonstrated the infectivity of this disease in a chimpanzee model. Gajdusek received the 1976 Nobel Prize in Physiology or Medicine for this achievement, and kuru research became a decisive foundation for establishing the overall concept of prion diseases.
The history of spongiform encephalopathy also begins with scrapie in sheep. Scrapie is a wasting neurological disease known in sheep for hundreds of years, with records observed on farms in England and Europe in the 18th century. In 1936, French researchers experimentally demonstrated that scrapie is transmitted between sheep by inoculation of brain homogenate, and subsequently the finding of typical spongiform vacuolar degeneration in brain tissue on neuropathological examination established the category of spongiform encephalopathy. In 1982, Stanley Prusiner proposed that the cause of this group of diseases is the prion, an infectious agent composed solely of protein without nucleic acid, and the modern concept of prion disease became established.
In 1986 in the United Kingdom, a new spongiform encephalopathy in cattle, bovine spongiform encephalopathy (BSE), the so-called "mad cow disease," was first reported. BSE is understood to be the result of amplification and transmission of prions through the use of ruminant-derived meat and bone meal as cattle feed. When an epidemiological and experimental link between BSE and human variant CJD (vCJD) was established in the mid-1990s, spongiform encephalopathy emerged as a worldwide public health agenda.
The cause of subacute spongiform encephalopathy is the accumulation of prion (PrPSc). The core of the pathogenesis is the structural conversion of the normal cellular prion protein (PrPC) into the abnormal isoform PrPSc, and PrPSc is characterized by protease resistance, aggregation and cytotoxicity. This conversion can be initiated spontaneously (sporadic), by genetic predisposition (genetic), or by the entry of external PrPSc (acquired).
Spongiform encephalopathy in humans is not limited to CJD alone. Gerstmann-Sträussler-Scheinker syndrome (GSS) is an autosomal dominant inherited prion disease characterized by cerebellar ataxia and dementia, caused by specific point mutations of the PRNP gene (especially P102L). Fatal familial insomnia (FFI) is caused by the combination of the PRNP D178N mutation and codon 129 methionine (Met) homozygosity, and is characterized by intractable insomnia and autonomic dysfunction. Sporadic fatal insomnia (SFI) has also been rarely reported.
Spongiform encephalopathies occurring in animals include scrapie in sheep and goats, BSE in cattle, chronic wasting disease (CWD) in deer and elk, transmissible mink encephalopathy (TME) in mink, and feline spongiform encephalopathy (FSE) in cats. Each has its own epidemiological characteristics and prion strain characteristics.
The PRNP gene (20p13) plays a central role in all human prion diseases. The methionine (M)/valine (V) polymorphism at PRNP codon 129 greatly affects disease susceptibility and clinical phenotype. Met/Met (MM) homozygotes have high susceptibility to prion infection, and the proportion of MM is very high among patients with sporadic CJD and variant CJD. The Val/Val (VV) or Met/Val (MV) phenotype shows relatively lower susceptibility, and the clinical phenotype may also differ.
GSS is caused by various point mutations of the PRNP gene, such as P102L, P105L, A117V and F198S, and is transmitted by autosomal dominant inheritance. FFI occurs when the D178N mutation is present together with Met at codon 129; even with the same D178N mutation, when codon 129 is Val it presents as a form of CJD (fCJD-178N). That the clinical phenotype differs according to the codon 129 polymorphism even with the same PRNP mutation is an important characteristic of prion biology.
Even for the same PrPSc, different prion strains exist depending on subtle differences in secondary and tertiary structure. Each strain shows its own incubation period, distribution of brain lesions and clinical phenotype. The strain concept suggests that genetic information can be transmitted by protein structure alone, without nucleic acid, which is one of the most intriguing aspects of prion biology.
The annual incidence of all human prion diseases is estimated at about 1–2 per million population. Of these, sporadic CJD is the most common (about 85%), GSS occurs in 0.01–0.05 per million, and FFI is even rarer, having been reported in only a few dozen families worldwide.
Scrapie has occurred continuously for hundreds of years in sheep populations in the United Kingdom, Europe, North America and Asia, but there is no evidence of human infection. BSE peaked in the United Kingdom in 1986–1996, with more than 180,000 cattle confirmed, and subsequently spread to dozens of countries worldwide. CWD is spreading rapidly among cervids in North America, and the possibility of human infection is under continuous monitoring.
Genetic prion diseases occur in clusters in particular regions or ethnic groups. Genetic CJD due to the E200K mutation occurs at a high frequency among Libyan Jews in Israel, and clusters have also been reported in parts of Slovakia and Chile. Most countries worldwide operate national surveillance systems for prion diseases including CJD, and in Europe the EuroCJD collaborative surveillance network is active.
As the name of subacute spongiform encephalopathy indicates, the most characteristic neuropathological finding is spongiform vacuolation of the neuropil. These vacuoles are known to originate mainly from the cell bodies and dendrites of neurons and sometimes from axons and astrocytic processes, but the exact mechanism of their formation has not yet been fully elucidated. Endoplasmic reticulum stress due to PrPSc accumulation, lysosomal pathway abnormalities and mitochondrial dysfunction are involved in combination, and disruption of ion homeostasis and cell swelling are known to contribute to vacuole formation.
Neuronal loss and reactive astrogliosis accompany spongiform degeneration. Reactive proliferation of astrocytes and fibrillary gliosis are important findings in neuropathological diagnosis. Activation of microglia is also observed, and it has been suggested that neuroinflammatory responses may aggravate progressive brain injury.
In some prion diseases (especially GSS, variant CJD and kuru), amyloid plaques composed of PrPSc are deposited in brain tissue. "Florid" plaques are characteristic of kuru and variant CJD, and multicentric plaques of GSS. In contrast, sporadic CJD often shows scattered PrPSc deposition without distinct plaque formation. These differences are understood as the combined influence of differences in prion strain and PRNP genotype.
The clinical symptoms of subacute spongiform encephalopathy vary according to the underlying disease (CJD, GSS, FFI, etc.) and the prion strain, but progressive cognitive decline is a common main symptom. In CJD, rapidly progressive dementia over weeks to months occurs, accompanied by memory loss, poor concentration, disorientation and impaired judgment. In FFI, intractable insomnia appears as the main symptom before cognitive decline, and complete breakdown of sleep architecture, autonomic hyperactivity (tachycardia, hypertension, fever, sweating) and endocrine abnormalities are characteristic.
In GSS, cerebellar ataxia characteristically progresses slowly over a course of several years, and dementia appears late. In CJD, myoclonus and pyramidal and extrapyramidal signs are observed relatively early. In kuru, cerebellar symptoms are the main manifestation, and gait disturbance and limb tremor are prominent from the early stage of onset.
The terminal symptoms of human prion diseases generally converge on akinetic mutism, decorticate rigidity, dysphagia and loss of spontaneous movement. At this stage, complications such as aspiration pneumonia, urinary tract infection and pressure ulcers are life-threatening, and all human prion diseases ultimately follow a fatal course.
The most decisive element in the diagnosis of subacute spongiform encephalopathy is the neuropathological findings. On hematoxylin-eosin (H&E) staining of brain tissue, spongiform vacuolar degeneration of neurons and neuropil is identified. These vacuoles are colorless spaces 1–20 μm in diameter, distributed particularly in the cerebral cortex, basal ganglia, cerebellum and thalamus. Reactive proliferation of astrocytes (GFAP immunohistochemistry positive) and neuronal loss also accompany them.
On Western blot after proteinase K treatment, a resistant band specific for PrPSc is detected. The molecular weight pattern of PrPSc (including the ratio of glycosylated forms) is used for prion strain classification, which is classified as Western blot PrP types (type 1–4). On immunohistochemistry (IHC) staining, various patterns of PrPSc deposition such as synaptic, patchy and plaque-type are observed, and these also serve as a basis for strain classification.
The characteristic EEG findings in CJD (periodic sharp wave complexes, PSWC) and MRI DWI findings (cortical ribboning, high signal in the basal ganglia) are as described above. In FFI, positron emission tomography (PET) characteristically shows decreased glucose metabolism in the thalamus, and thalamic atrophy may also be observed on MRI. In GSS, cerebellar atrophy may be prominent on MRI.
The test performed first at the stage of clinical suspicion is cerebrospinal fluid (CSF) examination. Biomarkers such as CSF 14-3-3 protein, total tau and neurofilament light chain (NfL) are used to support the diagnosis. The RT-QuIC assay amplifies and detects PrPSc in CSF or nasal mucosal washings with high sensitivity and specificity, and is currently the most reliable antemortem biochemical screening test.
Unlike the EEG showing PSWC in CJD, polysomnography plays a decisive role in the diagnosis of FFI. On polysomnography in FFI, the normal sleep architecture (NREM and REM sleep) almost disappears and only abnormal sleep states are observed. This reflects reduced function of the thalamus, the main site of involvement in FFI.
Unlike the MRI DWI findings in CJD, in FFI thalamic hypometabolism on brain FDG-PET appearing from the early stage is used as a screening indicator. In GSS, clinical features and genetic testing (PRNP mutations) are the primary screening tools.
The final diagnosis of subacute spongiform encephalopathy is neuropathological confirmation through brain tissue biopsy or autopsy. The three key findings of spongiform degeneration, neuronal loss and reactive astrogliosis are confirmed in brain tissue, and the abnormal conformation of the prion protein is verified by immunohistochemical staining for PrPSc and Western blot. Clinicopathological subtypes are classified by the combination of prion PrP type classification (type 1–4) and PRNP codon 129 genotype.
When there is a family history or onset at a relatively young age, PRNP gene mutation testing is essential for diagnosis. Specific PRNP mutations are identified in GSS, FFI and genetic CJD, respectively. Along with diagnosis, genetic testing provides the basis for genetic counseling of family members.
The diagnosis of subacute spongiform encephalopathy requires an integrated approach that comprehensively interprets clinical symptoms, EEG, MRI, CSF biomarkers, genetic testing and neuropathological findings. It is classified into definite, probable and possible grades according to the diagnostic criteria of the WHO and individual countries, and the probable diagnosis system in particular is widely used in clinical practice for antemortem diagnosis.
At present there is no curative treatment for subacute spongiform encephalopathy. Various therapeutic strategies such as inhibiting PrPSc formation, clearing PrPSc and blocking neurotoxicity are being studied, and some promising results have been reported in preclinical animal models, but no drug has yet been shown to be effective in human clinical trials. The strategy of suppressing PRNP expression using antisense oligonucleotides (ASO) has recently shown positive results at the preclinical stage and is drawing attention.
The core of treatment is symptom relief and maintenance of quality of life. Clonazepam, valproate and others are used for myoclonus and seizures, and benzodiazepines or hypnotics are given for insomnia and anxiety. In FFI, the effect of sleep-inducing drugs is extremely limited, so a palliative-focused approach is needed. Comprehensive supportive care is provided, including nutritional support, pressure ulcer prevention, respiratory management and management of swallowing disorders.
Prions are resistant to ordinary disinfection methods, so invasive medical instruments used in treating CJD patients require special processing (autoclaving at 134°C, soaking in caustic soda, etc.). When handling high-risk tissues such as brain, spinal cord and eyes, standard infection prevention guidelines must be strictly followed, and unnecessary exposure should be minimized through training of medical staff.
All human prion diseases are fatal, and survival differs according to disease type. Sporadic CJD follows the most rapid course, with median survival of about 4–6 months. In GSS, cerebellar ataxia progresses slowly over several years before leading to dementia, and the mean survival is 2–10 years, markedly longer than in CJD. FFI follows a course of several months to several years (mean about 12–18 months) after onset.
The PRNP codon 129 polymorphism, prion strain type, age at onset and clinical subtype affect prognosis. There are cases in which very long survival has been reported in GSS with certain mutations, but this is exceptional. Through adequate palliative and supportive care, maintaining quality of life and preventing complications are possible, which plays an important role in making the patient's final period meaningful.
Human prion diseases place a deep psychological and social burden not only on the patients themselves but also on their families. In genetic disease, there is great anxiety about the genetic risk of other family members, and professional genetic counseling and psychological support services are needed. Connection with domestic and international support organizations for families of patients with rare diseases is also helpful.
Donation of blood, plasma, organs and tissues from patients with prion disease or from high-risk groups is prohibited. Many countries restrict blood donation from regions with high vCJD risk (mainly people who stayed in the United Kingdom in 1980–1996), based on the reporting of a very small number of cases of vCJD transmission through blood products.
Veterinary and public health measures are being implemented to reduce the risk of human infection from animal prion diseases such as BSE and CWD. The United Kingdom and the European Union have completely banned the use of animal protein in ruminant feed since the 1990s, and cattle suspected of BSE infection are slaughtered and disposed of. For CWD, caution is advised regarding consumption of meat from infected deer, and it is recommended to confirm that the meat of deer hunted in infected areas is CWD-negative.
Standard autoclaving alone cannot completely inactivate prions on instruments used in neurosurgical procedures and eye surgery, so medical institutions follow protocols such as treatment with caustic soda (NaOH) or disposal for instruments used on patients with suspected or confirmed CJD. Continuous monitoring of the emergence of new prion diseases and epidemiological changes through national prion surveillance systems is the core of public health prevention.